# psoriasis - gpt-5.6-luna

- Benchmark system: raw
- Repeat: 4
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 3907
- Completion tokens: 6079
- Reasoning tokens: 
- Total tokens: 9986
- API requests reported: 
- Elapsed seconds: 112.8
- Final benchmark system: raw; file rank 2/5; original repeat 4; model vendor: OpenAI

---
## 1. Overall biological interpretation

The lesional skin profile shows a strong, statistically robust psoriasis-associated transcriptional state characterized by:

1. **Activation of the IL-36/IL-20 inflammatory epithelial axis**, including marked induction of **IL36A, IL36G, IL19, IL20, IL26, IL36RN, TNIP3, IRAK2, and ZC3H12A**.
2. **Broad induction of epithelial antimicrobial and neutrophil-associated programs**, with very large increases in **DEFB4A/DEFB4B, DEFB103A/DEFB103B, S100A7, S100A8, S100A12, PI3, TCN1, and CXCR2**.
3. **Keratinocyte activation, hyperproliferation, and altered terminal differentiation**, supported by coordinated increases in **KRT6A, SPRR2A–G, LCE3A/LCE3D, SERPINB3/B4/B11/B13, GJB2/GJB6, KRT-associated epithelial genes, RRM2, and CCNE1**.
4. **Changes in epithelial lipid, phospholipid, and tissue-remodeling biology**, including **PLA2G4D, PLA2G4E, FABP5, HPSE, WNT5A, AKR1B10, and KYNU**.
5. **Possible inflammatory immune-cell recruitment or altered immune composition**, suggested by **S100A8/S100A12, CXCL13, GPR15LG, CXCR2, CD274, and TCN1/PLBD1**.

The results are highly convincing as a molecular signature of lesional psoriatic skin. However, the dataset does not by itself distinguish **intrinsic keratinocyte reprogramming** from increased abundance of infiltrating leukocytes, vascular cells, or other cell populations. It also demonstrates association rather than causation.

---

## 2. Core biological programs

### Program 1: IL-36/IL-20-centered inflammatory epithelial signaling

**Direction:** Upregulated in lesional skin.

**Major supporting genes:**  
**IL36A** log2FC 11.37, **IL36G** 5.68, **IL19** 7.58, **IL20** 5.67, **IL26** 4.36, **IL36RN** 3.01, **TNIP3** 7.28, **IRAK2** 2.08, **ZC3H12A** 3.85.

**Relevant standardized pathways:**

- **Reactome: Cytokine Signaling in Immune System**
- **KEGG: Cytokine–cytokine receptor interaction**
- **GO: cytokine-mediated signaling pathway; inflammatory response**
- More specifically, this pattern is consistent with the **IL-36 inflammatory signaling axis**, although a dedicated standardized pathway may not capture the full program.

**Interpretation:**  
The combination of strongly induced IL-36 family ligands with IL-19, IL-20, and IL-26 indicates activation of an inflammatory epithelial cytokine network rather than isolated induction of one cytokine. **IL36A and IL36G** are particularly notable because IL-36 signaling is closely linked to psoriasis-associated keratinocyte activation, amplification of inflammatory circuits, and neutrophil recruitment. The concurrent increase in **IL36RN**, which encodes an IL-36 receptor antagonist, may represent a compensatory response to strong pathway activation rather than effective suppression.

**Evidence strength:** **Strongly supported by the input dataset.** Multiple related cytokines and pathway regulators are independently and highly significant, with FDR values approximately \(10^{-83}\) to \(10^{-98}\). The biological interpretation is also concordant with established psoriasis literature.

**Limitations:**  
Expression of cytokine genes does not establish cytokine protein secretion, receptor activation, or cellular source. The dataset does not include receptor expression, phosphoproteomic evidence, or functional perturbation. IL-36 and IL-20 signaling may also be secondary to upstream IL-17/TNF or tissue injury responses, neither of which can be directly assessed from the supplied genes.

---

### Program 2: Epithelial antimicrobial and innate inflammatory defense

**Direction:** Upregulated.

**Major supporting genes:**  
**DEFB4A, DEFB4B, DEFB103A, DEFB103B, PI3, S100A7, S100A7A, S100A8, S100A12, TCN1, PLBD1, CXCR2, GPR15LG, HRH2.**

**Relevant standardized pathways:**

- **GO: antimicrobial humoral response**
- **GO: defense response to bacterium**
- **GO: innate immune response**
- **Reactome: Innate Immune System**
- **Hallmark: Inflammatory Response**

**Interpretation:**  
The coordinated induction of multiple beta-defensins and inflammatory S100 proteins indicates a highly activated antimicrobial epithelial state. **DEFB4A/DEFB4B and DEFB103A/DEFB103B** are especially consistent with psoriasis-associated epidermal innate defense. **S100A8 and S100A12** add a myeloid/neutrophil-associated inflammatory component, while **PI3** and **TCN1** are compatible with antimicrobial and granulocyte-associated biology. **CXCR2** suggests potential involvement of neutrophil trafficking, although its expression alone does not demonstrate altered cell migration.

**Evidence strength:** **Strong for the existence of an antimicrobial/inflammatory signature.** It is supported by several independent gene families, not one canonical disease marker. The direction and magnitude are highly consistent across defensins and S100 genes.

**Limitations:**  
Some genes in this program may be derived from infiltrating neutrophils or other myeloid cells rather than keratinocytes. Bulk-tissue expression cannot determine whether the program represents increased per-cell expression, increased cell abundance, or both. Antimicrobial gene induction is also not specific to psoriasis and can occur in infection, wound repair, and other inflammatory dermatoses.

---

### Program 3: Keratinocyte activation, cornification, and epidermal barrier remodeling

**Direction:** Upregulated.

**Major supporting genes:**  
**KRT6A, SPRR2A, SPRR2B, SPRR2D, SPRR2E, SPRR2F, SPRR2G, SPRR3, LCE3A, LCE3D, SERPINB3, SERPINB4, SERPINB11, SERPINB13, GJB2, GJB6, S100A7, S100A7A, RRM2, CCNE1.**

**Relevant standardized pathways:**

- **GO: keratinization**
- **GO: cornification**
- **GO: epidermis development**
- **GO: skin development**
- **Reactome: Formation of the cornified envelope**
- **Hallmark: Epithelial–Mesenchymal Transition** is not an ideal primary annotation here and should not be used merely because tissue remodeling genes are present.

**Interpretation:**  
The broad induction of small proline-rich proteins, late cornified envelope genes, keratins, serpins, and gap-junction components reflects a coordinated alteration of epidermal differentiation and barrier biology. **KRT6A** is consistent with activated, hyperproliferative keratinocytes, whereas **SPRR and LCE genes** indicate remodeling of the cornified envelope. **RRM2 and CCNE1** provide limited additional evidence for proliferative activity, but the supplied list is not sufficient to define a full cell-cycle program.

**Evidence strength:** **Strong for keratinocyte-state and barrier remodeling; moderate for proliferation specifically.** The interpretation is supported by multiple genes from several epithelial differentiation families and is compatible with known lesional psoriasis histology.

**Limitations:**  
The analysis does not provide histologic measures such as epidermal thickness or Ki-67 staining. Upregulation of differentiation genes can reflect altered proportions of epidermal layers rather than a uniform change in each keratinocyte. The absence of a broader proliferation signature means that “hyperproliferation” should be stated more cautiously than “keratinocyte activation and differentiation remodeling.”

---

### Program 4: Inflammatory leukocyte recruitment and immune-cell composition

**Direction:** Upregulated.

**Major supporting genes:**  
**S100A8, S100A12, CXCR2, CXCL13, GPR15LG, CD274, TCN1, PLBD1, PRKCQ, ADAP2.**

**Relevant standardized pathways:**

- **GO: leukocyte chemotaxis**
- **GO: leukocyte migration**
- **GO: cell adhesion and migration**
- **Reactome: Chemokine receptors bind chemokines**
- **KEGG: Cytokine–cytokine receptor interaction**

**Interpretation:**  
This group suggests increased inflammatory immune-cell presence and/or signaling in lesions. **S100A8/S100A12** are compatible with neutrophil and inflammatory myeloid activity. **CXCL13** may indicate organized or intensified immune recruitment, although its receptor **CXCR5** is not present in the supplied table. **CD274** suggests increased immune-regulatory or interferon-responsive activity, but does not establish functional immune suppression. **CXCR2** is compatible with neutrophil-related trafficking biology, but it is not a ligand-receptor interaction with CXCL13.

**Evidence strength:** **Moderate.** The signal is supported by multiple immune-associated genes, but it is particularly vulnerable to tissue-composition confounding. The strongest conclusion is that lesional samples contain or induce an inflammatory immune-associated transcriptional component.

**Limitations:**  
No leukocyte marker deconvolution, single-cell data, histology, or cell-count information is available. Some markers may also be expressed by activated epithelial cells. The precise immune populations involved cannot be inferred reliably from this list alone.

---

### Program 5: Eicosanoid/lipid metabolism and tissue-remodeling responses

**Direction:** Upregulated overall, with selected metabolic genes downregulated.

**Major supporting genes:**  
Upregulated: **PLA2G4D, PLA2G4E, FABP5, HPSE, WNT5A, AKR1B10, AKR1B15, KYNU, HABP2, ABCG4**.  
Downregulated: **BTC** log2FC −4.30, **CYP2W1** −4.70, **UGT3A2** −4.59, **SAPCD1** −2.94, **WAKMAR1** −5.63.

**Relevant standardized pathways:**

- **GO: lipid metabolic process**
- **GO: phospholipid metabolic process**
- **GO: extracellular matrix organization**
- **Reactome: Arachidonic acid metabolism**
- **Reactome: Metabolism of lipids**

**Interpretation:**  
The paired induction of **PLA2G4D/E** and **FABP5** is compatible with altered epidermal lipid handling and inflammatory lipid mediator biology. **HPSE** and **WNT5A** suggest extracellular matrix and tissue-remodeling components. **KYNU** may reflect altered tryptophan metabolism and inflammatory metabolic adaptation. The downregulation of several metabolic or epithelial-associated genes indicates that remodeling is not a uniform activation of all metabolic pathways.

**Evidence strength:** **Moderate to exploratory.** The biological direction is supported by several genes, but the set is more heterogeneous than the cytokine, antimicrobial, and keratinocyte programs.

**Limitations:**  
The genes do not directly demonstrate altered eicosanoid concentrations, barrier lipids, extracellular matrix degradation, or WNT pathway activity. Some genes may reflect changes in cell composition or differentiation state. Enrichment would need to be performed using the complete ranked gene list rather than this selected table.

---

## 3. Key genes and interaction modules

The following candidates are prioritized as modules or representative genes. Relationships are classified explicitly to avoid conflating co-expression with direct physical interaction.

### 1. IL36A–IL36G–IL36RN inflammatory module

- **Direction:** All upregulated; IL36A is among the strongest signals.
- **Role:** Central inflammatory epithelial cytokine axis.
- **Relationship type:**  
  - **Regulatory/pathway relationship:** IL36A and IL36G are ligands for the IL-36 receptor system; IL36RN encodes an antagonist of this signaling pathway.  
  - **Not established as a direct physical interaction** from this dataset.
- **Interpretation:** Strongest disease-relevant cytokine module in the table. The simultaneous increase in agonists and antagonist is compatible with pathway activation plus feedback regulation.
- **Evidence:** Direct differential expression, pathway co-membership, and established psoriasis literature. Protein activity remains unverified.

### 2. IL19–IL20–IL26 epithelial cytokine module

- **Direction:** Upregulated.
- **Role:** Amplification of inflammatory epithelial signaling and communication with immune cells.
- **Relationship type:** **Pathway co-membership and regulatory/network relationship**, not demonstrated direct physical interaction.
- **Interpretation:** Their coordinated induction supports a broader inflammatory cytokine state rather than an isolated IL-36 abnormality.
- **Evidence:** Direct dataset and cytokine-pathway annotation; causal ordering is unresolved.

### 3. DEFB4A/DEFB4B–DEFB103A/DEFB103B antimicrobial module

- **Direction:** Strongly upregulated.
- **Role:** Epidermal antimicrobial defense and inflammatory barrier response.
- **Relationship type:** **Functional/pathway co-membership**; defensin proteins may have related antimicrobial functions, but direct physical interaction is not implied.
- **Interpretation:** One of the most reproducible epithelial signatures in the dataset.
- **Evidence:** Direct expression data, GO/Reactome innate-defense annotations, and established disease-associated expression evidence.

### 4. S100A7–S100A8–S100A12 inflammatory module

- **Direction:** Upregulated.
- **Role:** Keratinocyte inflammatory signaling and myeloid/neutrophil-associated inflammation.
- **Relationship type:** **Co-expression and functional co-membership**. Some S100 proteins can form protein complexes in specific contexts, but direct physical interaction should not be inferred for the entire module from this transcriptomic result.
- **Interpretation:** Indicates a combination of epithelial alarmin activity and possible myeloid infiltration.
- **Evidence:** Direct differential expression and disease literature; cellular source is unresolved.

### 5. KRT6A–SPRR/LCE–SERPIN epithelial remodeling module

- **Direction:** Upregulated.
- **Role:** Activated keratinocytes, cornified-envelope remodeling, and altered epidermal differentiation.
- **Relationship type:** **Shared differentiation program and co-expression**, not direct physical interaction.
- **Interpretation:** Provides stronger evidence for a coordinated epithelial state than any single keratin or SPRR gene alone.
- **Evidence:** Multiple independent epithelial gene families, standardized epidermal-development annotations, and tissue-specific disease evidence.

### 6. GJB2–GJB6 epithelial junction module

- **Direction:** Upregulated.
- **Role:** Gap-junction and epithelial communication remodeling.
- **Relationship type:** Potential **protein-family/pathway relationship**; direct connexin interaction is context-dependent and not demonstrated by the current data.
- **Interpretation:** Consistent with altered epithelial connectivity and barrier organization.
- **Evidence:** Direct expression and epithelial-junction biology; functional impact in psoriasis is not established here.

### 7. PLA2G4D–PLA2G4E–FABP5 lipid-inflammatory module

- **Direction:** Upregulated.
- **Role:** Phospholipid remodeling, lipid mediator generation, and epidermal lipid handling.
- **Relationship type:** **Metabolic pathway co-membership**, not necessarily direct physical interaction.
- **Interpretation:** A plausible link between barrier disruption and inflammatory lipid signaling.
- **Evidence:** Direct dataset and lipid-metabolism annotations; lipid mediator measurements are required.

### 8. S100A8/S100A12–CXCR2 inflammatory recruitment module

- **Direction:** S100A8, S100A12, and CXCR2 upregulated.
- **Role:** Neutrophil-associated inflammation and recruitment.
- **Relationship type:** **Indirect or putative relationship** through inflammatory chemotaxis; no direct physical interaction is implied.
- **Interpretation:** Supports inflammatory cell recruitment but cannot define the recruited population.
- **Evidence:** Direct expression and known immune biology; bulk-tissue composition is a major alternative explanation.

### 9. CXCL13–immune organization signal

- **Direction:** CXCL13 upregulated.
- **Role:** Potential lymphoid-cell recruitment or organization of local immune responses.
- **Relationship type:** **Regulatory/chemokine signaling relationship** with its known receptor system; no matching receptor is present in the table, and no direct interaction can be inferred.
- **Interpretation:** Interesting but less securely connected to the dominant epidermal program than IL-36 or defensins.
- **Evidence:** Direct expression and chemokine biology; requires spatial and cellular validation.

### 10. CD274 immune-regulatory signal

- **Direction:** Upregulated.
- **Role:** Potential immune checkpoint and inflammatory feedback response.
- **Relationship type:** **Regulatory ligand–receptor biology**; direct functional engagement with PD-1-positive cells is not shown.
- **Interpretation:** May reflect interferon/inflammatory activation or increased immune-regulatory signaling in lesions.
- **Evidence:** Direct dataset and established immune-regulatory biology; no evidence here that PD-L1 is therapeutically actionable in psoriasis.

---

## 4. Validation priorities

### Priority 1 — Validate the IL-36/IL-20 epithelial inflammatory axis

**Classification:** Mechanistic hypothesis

**Why prioritize:**  
This is the most coherent disease-relevant cytokine module, with highly significant induction of multiple ligands and the antagonist **IL36RN**.

**Current dataset evidence:**  
Very large increases in **IL36A, IL36G, IL19, IL20, IL26, and IL36RN**, all with extremely low FDR values.

**External evidence:**  
Psoriasis literature supports IL-36 as an important amplifier of keratinocyte inflammation and neutrophilic disease. However, external evidence does not prove that IL-36 initiates disease in these samples; it may be downstream of IL-17/TNF, tissue injury, or microbial stimuli.

**Next step:**  
Measure IL-36A/G and IL-19/20 protein in lesional tissue or keratinocyte-conditioned media; assess receptor-pathway activation; perturb IL-36 signaling in primary lesional keratinocytes or organotypic skin models.

**Conclusion level:** **Supported hypothesis**, not established causality.

---

### Priority 2 — Resolve epithelial versus infiltrating-myeloid contributions

**Classification:** Confounding or composition check

**Why prioritize:**  
The antimicrobial signature is strong, but **S100A8, S100A12, TCN1, PLBD1, and CXCR2** may be influenced by inflammatory-cell abundance.

**Current dataset evidence:**  
Co-induction of epithelial defensins with myeloid/neutrophil-associated genes.

**External evidence:**  
Psoriatic plaques commonly contain increased immune infiltrates, while keratinocytes themselves can express several antimicrobial and S100-family genes. Thus, both explanations are biologically plausible.

**Next step:**  
Use single-cell or spatial transcriptomics, immunohistochemistry/immunofluorescence, and cell-type deconvolution with validated reference signatures. Compare expression per cell type and quantify neutrophil, T-cell, and keratinocyte abundance.

**Conclusion level:** **Established evidence** for an inflammatory tissue signature; **insufficient evidence** for the precise cellular source.

---

### Priority 3 — Test whether lipid remodeling contributes functionally to barrier dysfunction

**Classification:** Mechanistic hypothesis

**Why prioritize:**  
The coordinated induction of **PLA2G4D, PLA2G4E, FABP5, and AKR1B10/15** suggests a potentially important interface between epidermal barrier biology and inflammatory mediator production.

**Current dataset evidence:**  
Multiple lipid/phospholipid-related genes are upregulated, but the program is less internally uniform than the cytokine and defensin modules.

**External evidence:**  
Epidermal lipid abnormalities and lipid mediator pathways are recognized components of inflammatory skin disease. Nevertheless, transcript induction does not establish altered lipid flux or pathogenic importance.

**Next step:**  
Perform targeted lipidomics, barrier-function assays such as transepidermal water loss, enzyme activity assays, and perturbation of PLA2G4D/E or FABP5 in primary keratinocytes or organotypic skin.

**Conclusion level:** **Exploratory to supported hypothesis**, depending on replication.

---

### Priority 4 — Determine whether CXCL13 and CD274 define a clinically meaningful immune niche

**Classification:** Biomarker

**Why prioritize:**  
**CXCL13** and **CD274** are strongly and significantly upregulated and may identify a subset of lesions with distinct immune organization or inflammatory regulation.

**Current dataset evidence:**  
CXCL13 log2FC 5.89 and CD274 log2FC 3.44, both with very low FDR.

**External evidence:**  
Both genes have established roles in immune-cell communication, but their disease specificity and prognostic value in psoriasis are not established by this dataset. Their expression may vary with disease severity, treatment status, and immune-cell composition.

**Next step:**  
Replicate in independent lesional/nonlesional/control cohorts; relate expression to PASI score, treatment response, and histologic immune-cell density; perform spatial localization and protein validation.

**Conclusion level:** **Exploratory biomarker hypothesis.**

---

### Priority 5 — Validate the KRT6A–SPRR/LCE epithelial state as a tissue biomarker

**Classification:** Biomarker

**Why prioritize:**  
The epithelial remodeling program is broad, internally consistent, and likely to be robustly measurable in lesional tissue.

**Current dataset evidence:**  
Coordinated induction of **KRT6A, SPRR2 family genes, SPRR3, LCE3A/LCE3D, SERPINB3/B4, and GJB2/GJB6**.

**External evidence:**  
These gene families are well established as markers of activated or altered epidermal differentiation. However, they are not necessarily specific to psoriasis and can be induced in wound healing, irritant dermatitis, and other inflammatory conditions.

**Next step:**  
Validate by histology, immunostaining, qPCR or targeted RNA profiling, and comparison with atopic dermatitis, contact dermatitis, and wound-repair controls.

**Conclusion level:** **Established evidence** for epithelial remodeling in the analyzed lesions; **exploratory** as a disease-specific biomarker.

---

## 5. Evidence grounding and interpretation of relationships

- **Direct evidence from the supplied dataset:** Nearly all highlighted genes have large effect sizes and extremely low FDR values. This strongly supports differential expression, but not pathway activity, protein abundance, cellular localization, or causality.
- **Pathway/ontology evidence:** The IL-36/cytokine, antimicrobial-defense, keratinization, and lipid-metabolism interpretations are based on established functional annotations and multi-gene coherence.
- **Disease-association evidence:** The overall pattern is concordant with known psoriasis biology, particularly lesional keratinocyte activation, antimicrobial peptide induction, neutrophilic inflammation, and IL-36-associated signaling.
- **Protein-interaction evidence:** No direct protein interactions should be claimed solely from this table. Most proposed relationships are pathway co-membership, co-expression, or indirect regulatory relationships.
- **Expression/tissue evidence:** The profile is highly compatible with lesional epidermis and inflammatory infiltrates, but bulk tissue prevents definitive source assignment.
- **Genetic/clinical evidence:** No genotype, severity, treatment-response, or longitudinal clinical data were supplied. Therefore, no genetic causality or prognostic interpretation can be made.
- **Drug/therapeutic evidence:** The dataset alone does not establish any gene as a therapeutic target. A pathway being druggable would not demonstrate efficacy or disease selectivity.

The very low FDR values across many genes are statistically compelling, but the evidence is not fully independent: genes within the same pathway may be co-regulated by the same upstream inflammatory signals, and several external literature claims derive from overlapping psoriasis datasets.

---

## 6. Major limitations and alternative explanations

1. **Cellular composition effects**  
   Increased neutrophils, T cells, dendritic cells, or activated keratinocytes could drive parts of the signal. This is particularly important for **S100A8/A12, TCN1, PLBD1, CXCR2, CXCL13, and CD274**.  
   **Investigation:** single-cell/spatial profiling, deconvolution, and tissue immunostaining.

2. **Disease severity and lesion heterogeneity**  
   Large effect sizes may reflect highly inflamed plaques or a specific lesion stage rather than all psoriasis.  
   **Investigation:** correlate with PASI, lesion duration, histology, and replicate across patients and lesion types.

3. **Treatment exposure and clinical covariates**  
   Topical or systemic treatment, age, sex, recent infection, or comorbid inflammation could influence cytokine and barrier signatures.  
   **Investigation:** stratified analyses and carefully matched untreated controls.

4. **Association-versus-causation ambiguity**  
   IL-36, defensin, S100, and keratinocyte programs may be downstream consequences of upstream IL-17/TNF signaling, barrier injury, or microbial exposure.  
   **Investigation:** longitudinal sampling and perturbation experiments rather than cross-sectional expression alone.

5. **Bulk-tissue and annotation limitations**  
   Several loci are pseudogenes, long noncoding RNAs, or poorly characterized transcripts, including **VNN3P, LOC105376238, CERNA2, and multiple LOC genes**. Their large fold changes are statistically interesting but biologically difficult to interpret without transcript validation.  
   **Investigation:** verify transcript identity and mapping, use independent RNA-seq/qPCR assays, and avoid assigning function without orthogonal evidence.

Overall, the strongest and most biologically defensible conclusion is that the lesions exhibit a coordinated **IL-36-associated inflammatory, antimicrobial, and activated-keratinocyte state**, with additional evidence for immune-cell recruitment and lipid/barrier remodeling. The central uncertainties concern cellular source, upstream causality, and clinical specificity.
